Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy

Researchers measured procalcitonin levels in patients for 14 days (or hospital discharge) after receiving CAR T-cell therapy to evaluate its use as a biomarker for infection and sepsis. They found that patients diagnosed with sepsis had elevated PCT levels with a peak mean of 2.6 µg/L on day 7 following treatment compared with patients without infection, whose levels remained below 0.5 µg/L. These data support the use of procalcitonin levels in the risk-stratification and diagnosis of patients at high risk for infection following CAR T-cell therapy.